Developer docs
API playgroundTry for free, no card

Search company profiles

Neuraptive Therapeutics

Full company profile

uuid0000zd5

Namestring
Neuraptive Therapeutics
Legal namestring
Neuraptive Therapeutics, Inc.
Websiteurl
neuraptive.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Neuraptive Therapeutics is a clinical-stage biotechnology company developing NTX-001, a surgical treatment kit designed to repair severed peripheral nerves. The product is built on PEG-FUSION technology — the application of polyethylene glycol (PEG) via sequenced reagents to a nerve coaptation (neurorrhaphy) to fuse proximal and distal axonal membranes and prevent Wallerian degeneration. NTX-001 is positioned as an adjunct to standard suture neurorrhaphy and integrates three components: the PEG-FUSION chemistry, a proprietary drug delivery device for topical administration of active agents onto the nerve, and nerve-specific microsurgical instruments. The company is pursuing the FDA 505(b)(2) regulatory pathway using previously approved pharmaceutical ingredients presented in sterile solutions.

The company was founded in 2016 and is headquartered in Chesterbrook, Pennsylvania. Its core intellectual property is in-licensed from the University of Texas at Austin, with patent protection extending through 2038, supplemented by Neuraptive's own patent applications on the delivery device, formulation, and kit design. Neuraptive has secured three FDA designations for NTX-001: Fast Track Designation (May 2020), Orphan Drug Designation (January 2024), and Breakthrough Therapy Designation (September 2024). Two Phase 2 multi-center trials have been completed and Phase 3 enrollment began in October 2025 for upper extremity transected nerves, with a parallel Phase 2 program ongoing for prevention of postoperative facial paralysis.

The company is pre-revenue with no products approved or on market. Its target end users are surgeons and physicians specializing in peripheral nerve repair — including trauma, reconstructive, and facial nerve surgeons — operating in hospitals and surgical centers. The intended go-to-market is direct enterprise field sales to these institutions upon regulatory approval, leveraging the well-established reimbursement infrastructure for nerve repair procedures. Total disclosed funding is approximately $20 million across seed (2017), Series A led by New Rhein Healthcare Investors (2018), and a Ben Franklin Technology Partners financing (2022).

Short descriptiontext

Neuraptive Therapeutics is a clinical-stage biotechnology company developing NTX-001, a PEG-FUSION-based surgical kit for repairing peripheral nerve injuries, targeting hospitals and surgeons with FDA Fast Track, Orphan Drug, and Breakthrough Therapy Designations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLafayette, United States
HQ citystring
Lafayette
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peripheral nerve repair, nerve fusion therapeutics, biopharmaceutical development, surgical medical devices, clinical stage biotechnology
Industry1 code
PRIMARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Peripheral Nerve Repair Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1NTX-001 Product Sales
TypeOne Time License
Description

Pre-commercial biotech company developing NTX-001, a surgical treatment kit for peripheral nerve repair. Revenue will come from product sales to hospitals and surgical centers upon regulatory approval. The company has two Phase 2 multi-center clinical trials completed and is enrolling in Phase 3 clinical trials.

neuraptive.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neuraptive Therapeutics develops NTX-001, a surgical treatment kit for repairing severed peripheral nerves. NTX-001 integrates three components: (1) PEG-FUSION technology using polyethylene glycol to fuse axonal membranes of severed nerve stumps, (2) a specialized drug delivery device for topical administration of active agents on the nerve, and (3) nerve-specific microsurgical instruments. The product is being advanced through Phase 3 clinical trials under the 505(b)(2) regulatory pathway.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • PEG-FUSION in combination with standard neurorrhaphy is superior in improving functional outcomes following peripheral nerve injury compared to standard neurorrhaphy alone
Product overview1 text field

Neuraptive Therapeutics is a biotechnology company developing the NTX-001 surgical treatment kit for peripheral nerve injuries. NTX-001 is a unified product comprising three integrated components: (1) PEG-FUSION nerve fusion technology using polyethylene glycol to fuse severed nerve endings, (2) a specialized drug delivery device for topical administration of active agents on nerves, and (3) proprietary microsurgical instruments designed for nerve repair procedures. The company also holds patent protection through 2038 for the NTX-001 technology licensed from the University of Texas at Austin.

Product and service1 record
1NTX-001
CategorySurgical nerve repair product kit
Description

A surgical treatment kit for repairing severed peripheral nerves after trauma or peripheral nerve reconstruction procedures. Combines PEG-FUSION nerve fusion technology (using polyethylene glycol-based sequenced reagents applied to freshly coapted nerve endings to fuse axonal membranes and prevent Wallerian degeneration) with a specialized drug delivery device for topical administration of active agents and proprietary microsurgical instruments. Developed under the FDA 505(b)(2) pathway using previously approved pharmaceutical ingredients presented in sterile solutions. Intended for use by surgeons at hospitals and surgical centers performing peripheral nerve repair procedures.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

Neuraptive has in-licensed technology from the University of Texas at Austin protecting a novel fusion system for repairing severed peripheral nerves. The in-licensed and issued patent estate protects the method of repairing nerves embodied in NTX-001. Patent protections expected to extend through 2038.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Axogen is the dominant commercial player in peripheral nerve repair with products including Avance nerve graft, Axoguard nerve cap, and Acroval connectors. It is the most directly comparable competitor to Neuraptive, addressing the same surgical specialty and patient population (peripheral nerve injuries) but with a tissue-based graft and connector portfolio rather than a chemical fusion approach.

TypeBroad incumbent
Description

Integra LifeSciences is a large diversified medical device company with a peripheral nerve repair portfolio (e.g., NeuraGen nerve guide, NeuraWrap) and broader regenerative tissue technologies. It serves the same surgeon customers and patient population as Neuraptive but as part of a much larger portfolio spanning neurosurgery, ENT, and reconstructive surgery.

TypeBroad incumbent
Description

Stryker is a major diversified medical device and surgical equipment company with products used in trauma, orthopedic, and reconstructive surgical settings — including those where peripheral nerve repair procedures occur. While it does not have a dedicated nerve fusion product, its broad surgical footprint and hospital relationships make it a relevant incumbent peer and potential strategic acquirer.

TypeBroad incumbent
Description

Medtronic is a global medical device leader with neuromodulation and neurosurgery franchises that overlap indirectly with peripheral nerve applications. It addresses related but distinct indications (spinal cord stimulation, deep brain stimulation) and could be a strategic partner or acquirer given the convergence of nerve repair and neuromodulation.

TypeDirect peer
Description

Checkpoint Surgical develops nerve stimulation and monitoring devices used during surgery, including the Checkpoint Stimulator/Locator for intra-operative nerve identification. While its focus is on nerve preservation and stimulation rather than repair, it serves the same surgical specialties and addresses complementary unmet needs in peripheral nerve surgery.

TypeDirect peer
Description

Polyganics is a Netherlands-based medical device company developing bioresorbable nerve repair devices such as the Neurolac nerve guide for peripheral nerve injuries. It competes directly with Neuraptive in the surgical peripheral nerve repair market, with a complementary product approach (synthetic conduits vs. PEG fusion).

TypeEmerging player
Description

Tissium is a Paris-based medtech developing programmable biomaterials for tissue reconstruction, including nerve repair applications. It shares the philosophy of enabling natural tissue repair with Neuraptive's PEG-FUSION approach and is an emerging competitor in the same surgical specialty space.

8Abbott Laboratories
TypeBroad incumbent
Description

Abbott is a large diversified medical device and diagnostics company with neuromodulation products and broad surgical/electromedical device portfolios. While not a direct competitor in peripheral nerve fusion, it operates in adjacent nerve stimulation and surgical device categories and could represent a strategic exit path for Neuraptive.

TypeBroad incumbent
Description

Boston Scientific is a global medical device leader with significant neuromodulation, peripheral intervention, and pain management franchises. Although its nerve-related products focus on stimulation rather than surgical repair, it is a relevant incumbent with similar hospital channels and could be a strategic acquirer.

TypeEmerging player
Description

Cohera Medical develops surgical adhesives and sealants used in tissue repair procedures. While its products are not specifically indicated for peripheral nerve repair, its chemical adhesion technology is philosophically adjacent to PEG-FUSION and represents a comparable emerging tissue repair platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neuraptive Therapeutics

Peripheral Nerve Repair Therapeuticsneuraptive.com

Neuraptive Therapeutics is a clinical-stage biotechnology company developing NTX-001, a PEG-FUSION-based surgical kit for repairing peripheral nerve injuries, targeting hospitals and surgeons with FDA Fast Track, Orphan Drug, and Breakthrough Therapy Designations.

What Neuraptive Therapeutics does

Neuraptive Therapeutics is a clinical-stage biotechnology company developing NTX-001, a surgical treatment kit designed to repair severed peripheral nerves. The product is built on PEG-FUSION technology — the application of polyethylene glycol (PEG) via sequenced reagents to a nerve coaptation (neurorrhaphy) to fuse proximal and distal axonal membranes and prevent Wallerian degeneration. NTX-001 is positioned as an adjunct to standard suture neurorrhaphy and integrates three components: the PEG-FUSION chemistry, a proprietary drug delivery device for topical administration of active agents onto the nerve, and nerve-specific microsurgical instruments. The company is pursuing the FDA 505(b)(2) regulatory pathway using previously approved pharmaceutical ingredients presented in sterile solutions.

The company was founded in 2016 and is headquartered in Chesterbrook, Pennsylvania. Its core intellectual property is in-licensed from the University of Texas at Austin, with patent protection extending through 2038, supplemented by Neuraptive's own patent applications on the delivery device, formulation, and kit design. Neuraptive has secured three FDA designations for NTX-001: Fast Track Designation (May 2020), Orphan Drug Designation (January 2024), and Breakthrough Therapy Designation (September 2024). Two Phase 2 multi-center trials have been completed and Phase 3 enrollment began in October 2025 for upper extremity transected nerves, with a parallel Phase 2 program ongoing for prevention of postoperative facial paralysis.

The company is pre-revenue with no products approved or on market. Its target end users are surgeons and physicians specializing in peripheral nerve repair — including trauma, reconstructive, and facial nerve surgeons — operating in hospitals and surgical centers. The intended go-to-market is direct enterprise field sales to these institutions upon regulatory approval, leveraging the well-established reimbursement infrastructure for nerve repair procedures. Total disclosed funding is approximately $20 million across seed (2017), Series A led by New Rhein Healthcare Investors (2018), and a Ben Franklin Technology Partners financing (2022).

Neuraptive Therapeutics firmographics

Firmographics
Name
Neuraptive Therapeutics
Legal name
Neuraptive Therapeutics, Inc.
Website
https://neuraptive.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Neuraptive Therapeutics is a clinical-stage biotechnology company developing NTX-001, a PEG-FUSION-based surgical kit for repairing peripheral nerve injuries, targeting hospitals and surgeons with FDA Fast Track, Orphan Drug, and Breakthrough Therapy Designations.
Ownership category
akta.pro rank

Neuraptive Therapeutics industry classification

Industry
Product category
Peripheral Nerve Repair Therapeutics
NAICS
Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Peripheral nerve repair
  • Nerve fusion therapeutics
  • Biopharmaceutical development
  • Surgical medical devices
  • Clinical stage biotechnology

Where Neuraptive Therapeutics is headquartered

Location

Headquarters

HQ city
Lafayette
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Neuraptive Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. NTX-001 Product Sales: Pre-commercial biotech company developing NTX-001, a surgical treatment kit for peripheral nerve repair. Revenue will come from product sales to hospitals and surgical centers upon regulatory approval. The company has two Phase 2 multi-center clinical trials completed and is enrolling in Phase 3 clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Neuraptive Therapeutics product offering

Product offering

Core offering

Neuraptive Therapeutics develops NTX-001, a surgical treatment kit for repairing severed peripheral nerves. NTX-001 integrates three components: (1) PEG-FUSION technology using polyethylene glycol to fuse axonal membranes of severed nerve stumps, (2) a specialized drug delivery device for topical administration of active agents on the nerve, and (3) nerve-specific microsurgical instruments. The product is being advanced through Phase 3 clinical trials under the 505(b)(2) regulatory pathway.

Product overview

Neuraptive Therapeutics is a biotechnology company developing the NTX-001 surgical treatment kit for peripheral nerve injuries. NTX-001 is a unified product comprising three integrated components: (1) PEG-FUSION nerve fusion technology using polyethylene glycol to fuse severed nerve endings, (2) a specialized drug delivery device for topical administration of active agents on nerves, and (3) proprietary microsurgical instruments designed for nerve repair procedures. The company also holds patent protection through 2038 for the NTX-001 technology licensed from the University of Texas at Austin.

Differentiator

Problem solved

Functional benefit

Products and services

  • NTX-001 A surgical treatment kit for repairing severed peripheral nerves after trauma or peripheral nerve reconstruction procedures. Combines PEG-FUSION nerve fusion technology (using polyethylene glycol-based sequenced reagents applied to freshly coapted nerve endings to fuse axonal membranes and prevent Wallerian degeneration) with a specialized drug delivery device for topical administration of active agents and proprietary microsurgical instruments. Developed under the FDA 505(b)(2) pathway using previously approved pharmaceutical ingredients presented in sterile solutions. Intended for use by surgeons at hospitals and surgical centers performing peripheral nerve repair procedures.

Quantifiable outcome

  • PEG-FUSION in combination with standard neurorrhaphy is superior in improving functional outcomes following peripheral nerve injury compared to standard neurorrhaphy alone

Companies that use Neuraptive Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Neuraptive Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Neuraptive Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • University of Texas at AustincoreTechnology or IntegrationNeuraptive has in-licensed technology from the University of Texas at Austin protecting a novel fusion system for repairing severed peripheral nerves. The in-licensed and issued patent estate protects the method of repairing nerves embodied in NTX-001. Patent protections expected to extend through 2038.

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

Neuraptive Therapeutics competitors and assessment

Company assessment

Direct peers

  • Axogen: Axogen is the dominant commercial player in peripheral nerve repair with products including Avance nerve graft, Axoguard nerve cap, and Acroval connectors. It is the most directly comparable competitor to Neuraptive, addressing the same surgical specialty and patient population (peripheral nerve injuries) but with a tissue-based graft and connector portfolio rather than a chemical fusion approach.
  • Checkpoint Surgical: Checkpoint Surgical develops nerve stimulation and monitoring devices used during surgery, including the Checkpoint Stimulator/Locator for intra-operative nerve identification. While its focus is on nerve preservation and stimulation rather than repair, it serves the same surgical specialties and addresses complementary unmet needs in peripheral nerve surgery.
  • Polyganics: Polyganics is a Netherlands-based medical device company developing bioresorbable nerve repair devices such as the Neurolac nerve guide for peripheral nerve injuries. It competes directly with Neuraptive in the surgical peripheral nerve repair market, with a complementary product approach (synthetic conduits vs. PEG fusion).

Broad incumbents

  • Integra LifeSciences: Integra LifeSciences is a large diversified medical device company with a peripheral nerve repair portfolio (e.g., NeuraGen nerve guide, NeuraWrap) and broader regenerative tissue technologies. It serves the same surgeon customers and patient population as Neuraptive but as part of a much larger portfolio spanning neurosurgery, ENT, and reconstructive surgery.
  • Stryker: Stryker is a major diversified medical device and surgical equipment company with products used in trauma, orthopedic, and reconstructive surgical settings — including those where peripheral nerve repair procedures occur. While it does not have a dedicated nerve fusion product, its broad surgical footprint and hospital relationships make it a relevant incumbent peer and potential strategic acquirer.
  • Medtronic: Medtronic is a global medical device leader with neuromodulation and neurosurgery franchises that overlap indirectly with peripheral nerve applications. It addresses related but distinct indications (spinal cord stimulation, deep brain stimulation) and could be a strategic partner or acquirer given the convergence of nerve repair and neuromodulation.
  • Abbott Laboratories: Abbott is a large diversified medical device and diagnostics company with neuromodulation products and broad surgical/electromedical device portfolios. While not a direct competitor in peripheral nerve fusion, it operates in adjacent nerve stimulation and surgical device categories and could represent a strategic exit path for Neuraptive.
  • Boston Scientific: Boston Scientific is a global medical device leader with significant neuromodulation, peripheral intervention, and pain management franchises. Although its nerve-related products focus on stimulation rather than surgical repair, it is a relevant incumbent with similar hospital channels and could be a strategic acquirer.

Emerging players

  • Tissium: Tissium is a Paris-based medtech developing programmable biomaterials for tissue reconstruction, including nerve repair applications. It shares the philosophy of enabling natural tissue repair with Neuraptive's PEG-FUSION approach and is an emerging competitor in the same surgical specialty space.
  • Cohera Medical: Cohera Medical develops surgical adhesives and sealants used in tissue repair procedures. While its products are not specifically indicated for peripheral nerve repair, its chemical adhesion technology is philosophically adjacent to PEG-FUSION and represents a comparable emerging tissue repair platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Neuraptive Therapeutics social profiles

Digital presence

Neuraptive Therapeutics compliance and trust

Trust signal

Compliance3 records

Neuraptive Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neuraptive Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Neuraptive Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neuraptive Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuraptive Therapeutics

What does Neuraptive Therapeutics do?

Neuraptive Therapeutics develops NTX-001, a surgical treatment kit for repairing severed peripheral nerves. NTX-001 integrates three components: (1) PEG-FUSION technology using polyethylene glycol to fuse axonal membranes of severed nerve stumps, (2) a specialized drug delivery device for topical administration of active agents on the nerve, and (3) nerve-specific microsurgical instruments. The product is being advanced through Phase 3 clinical trials under the 505(b)(2) regulatory pathway.

Is Neuraptive Therapeutics a public or private company?

Neuraptive Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Neuraptive Therapeutics founded?

Neuraptive Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Neuraptive Therapeutics based?

Neuraptive Therapeutics is headquartered in Lafayette, United States, in the North America region.

How does Neuraptive Therapeutics make money?

One revenue line is on record: NTX-001 Product Sales.

Who are Neuraptive Therapeutics's main competitors?

Direct peers on record are Axogen, Checkpoint Surgical and Polyganics. Broad incumbents are Integra LifeSciences, Stryker, Medtronic, Abbott Laboratories and Boston Scientific. Emerging players are Tissium and Cohera Medical.

Does Neuraptive Therapeutics have an API?

No public API is recorded for Neuraptive Therapeutics.

What industry is Neuraptive Therapeutics in?

Neuraptive Therapeutics's product category is Peripheral Nerve Repair Therapeutics. Its primary akta.pro industry code is HLAAAGAI, Neural & Spinal Cord Regeneration. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkNeuraptive secures exclusive licence from Washington University for nerve deviceNeuraptive Therapeutics has secured an exclusive licence from Washington University in St Louis for a bioresorbable wireless electronic stimulation device designed for peripheral nerve repair. The technology, developed at Washington University School of Medicine in collaboration with Northwestern University, delivers targeted electrical pulses to damaged nerves and naturally breaks down in the body over time, eliminating the need for removal surgery. The newly licensed device will be added to Neuraptive's existing portfolio alongside NTX-001, the company's nerve fusion system currently undergoing Phase III clinical trials.FinanzNachrichten.deNeuraptive Therapeutics, Inc.: Neuraptive Therapeutics erhält Lizenz für innovative, bioresorbierbare Nervenstimulationstechnologie von der Washington University in St. LouisNeuraptive Therapeutics secured an exclusive license from Washington University in St. Louis for a bioresorbable wireless electronic nerve stimulation device developed by WashU Medicine researchers in collaboration with Northwestern University. The device delivers targeted electrical impulses to injured peripheral nerves to accelerate regeneration and naturally dissolves in the body without requiring surgical removal. The technology complements Neuraptive's existing pipeline, including the Phase 3-stage NTX-001 nerve fusion system, with financial terms of the license undisclosed.Business Wire BlogNeuraptive Therapeutics Licenses Innovative Bioresorbable Nerve Stimulation Technology from Washington University in St. LouisNeuraptive Therapeutics, a clinical-stage biotech company focused on peripheral nerve injuries, has secured an exclusive license from Washington University in St. Louis for a bioresorbable wireless electronic stimulation device. The technology, developed by researchers at WashU Medicine in collaboration with Northwestern University, delivers targeted electrical pulses to damaged nerves to accelerate regeneration and eliminates the need for follow-up removal surgery. The new device complements Neuraptive's existing pipeline, including NTX-001, which is currently in a Phase 3 trial for surgical repair of transected peripheral nerves.AETOSWireNeuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral NervesNeuraptive Therapeutics announced proof of concept for NTX-001 in the NEUROFUSE study, a 48-week trial of 60 patients. Fifty-one patients were included; NTX-001 showed fewer adverse events and significant improvements in pain and global impression at 12 weeks, with a significant separation at 8 weeks. The company plans late-phase confirmatory trials.AETOSWireNeuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week DataNeuraptive Therapeutics announced 24-week data from the NEUROFUSE Phase 2a study for NTX-001, showing sustained safety and efficacy as an adjunct for transected peripheral nerves. The drug improved hand function and pain scores versus standard care, with lower adverse event rates. The company plans to present top-line results and seek an FDA End of Phase 2 meeting.AETOSWireNeuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical RepairNeuraptive Therapeutics announced the first patient enrolled in its phase 3 trial of NTX-001 for upper extremity transected nerves requiring surgical repair. The multicenter, randomized study will enroll about 110 patients across 24 US sites, comparing NTX-001 to standard of care. The trial is supported by a Department of Defense award.BioSpaceNeuraptive Therapeutics Licenses Innovative Bioresorbable Nerve Stimulation Technology from Washington University in St. LouisNeuraptive Therapeutics secured an exclusive license from Washington University in St. Louis for a bioresorbable wireless nerve stimulation device. The device delivers targeted electrical pulses to damaged nerves and breaks down naturally, complementing Neuraptive's lead product NTX-001 in a Phase 3 trial. Financial terms were not disclosed.Financial PostNeuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company's Advancement Toward CommercializationNeuraptive Therapeutics announced the appointment of Ulf Wiinberg to its Board of Directors and the hiring of William "Bill" MacKenzie as Senior Vice President – Finance. Wiinberg brings extensive biotech and pharmaceutical executive experience, including serving as CEO of X-Vax Technology and Lundbeck, while MacKenzie brings over a decade of biotech financial leadership from companies including Sage Therapeutics and Prelude Therapeutics. The company stated these appointments are intended to support its advancement toward commercialization of NTX-001.AETOSWireNeuraptive Therapeutics, Inc. Announces Key Organizational Updates to Support the Company’s Advancement Toward Commercia...Neuraptive Therapeutics appointed Ulf Wiinberg to its Board of Directors and William MacKenzie as Senior Vice President of Finance. Wiinberg previously led X-Vax and Lundbeck, while MacKenzie has over a decade of biotech financial leadership. The appointments aim to support the company's commercialization strategy for peripheral nerve injury therapeutics.